Quarterly ResultMay 4, 2026, 04:15 PM
ORIC Pharma Selects Rinzimetostat Phase 3 Dose; Q1 Net Loss $(35.8)M
AI Summary
ORIC Pharmaceuticals announced its Q1 2026 financial results and significant operational updates. The company selected rinzimetostat 400 mg once daily as the Recommended Phase 3 Dose for the Himalayas-1 global registrational trial in post-abiraterone mCRPC, expected to start in 1H 2026. Clinical data for rinzimetostat showed a strong safety profile and promising rPFS rates, supporting its potential as a best-in-disease candidate. The company reported a net loss of $(35.8) million for the quarter and maintains a strong cash position of $419.7 million, providing a runway into 2H 2028.
Key Highlights
- Selected rinzimetostat 400 mg as Phase 3 dose for Himalayas-1 trial in mCRPC.
- Himalayas-1 global Phase 3 trial expected to initiate in 1H 2026.
- Rinzimetostat showed 5-month rPFS of 84% in post-abiraterone mCRPC.
- Q1 2026 net loss was $(35.8) million, compared to $(30.0) million in Q1 2025.
- R&D expenses increased to $31.4 million in Q1 2026 from $24.6 million YoY.
- Cash, cash equivalents, and investments totaled $419.7 million as of March 31, 2026.
- Cash runway expected to last into 2H 2028.